{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-013762","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.883012+00:00","generated_at":"2026-06-15T04:15:27.478210+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin reports Q1 2023 cash of $37.3M, R&D expense up to $5.7M; Annamycin trial advances","bullets":["Cash and equivalents of $37.3M as of March 31, 2023, expected to fund operations into Q3 2024.","R&D expense increased to $5.7M from $4.6M YoY, primarily due to WPD sublicense termination.","G&A expense increased to $2.6M from $2.4M YoY, driven by higher regulatory, legal, and consulting fees.","Phase 1b/2 trial of Annamycin in AML (MB-106) completed first cohort; positive preclinical data presented at AACR 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-013762","json":"https://secwatch.observer/filing/0001437749-23-013762.json","markdown":"https://secwatch.observer/filing/0001437749-23-013762.md","text":"https://secwatch.observer/filing/0001437749-23-013762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/0001437749-23-013762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/mbrx20230508c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:15:27.478210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9155cb60cc96bc3c98dccd81e869f0ef27b0ad4","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923013762/0001437749-23-013762-index.htm","confidence":0.96,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}